Literature DB >> 35237110

Limitations and Concerns with Transanal Total Mesorectal Excision for Rectal Cancer.

M Vannijvel1, Albert M Wolthuis1.   

Abstract

Transanal total mesorectal excision (TaTME) was developed to overcome the technical challenges of a minimally invasive (ultra-) low anterior resection. This new technique has recently come under careful scrutiny as technical pitfalls were reported, in specific relation to the transanal approach. Patients are at risk for urologic lesions. Moreover, carbon dioxide embolism is a rare but potentially life-threatening complication. The benefit of TaTME from an oncological point of view has neither been clarified. Hypothetically, better visualization of the lower rectum could lead to better dissection and total mesorectal excision (TME) specimens, resulting in better oncologic results. Up until now, retrospective multicenter reports seem to show that short-term oncologic results are not inferior after TaTME as compared with after laparoscopic TME. Alarming reports have however been published from Norway suggesting a high incidence and particular multifocal pattern of early local recurrence. In this article, a balanced overview is given of the most important technical pitfalls and oncological concerns arising with this new procedure. Thieme. All rights reserved.

Entities:  

Keywords:  complications; rectal cancer; transanal total mesorectal excision

Year:  2022        PMID: 35237110      PMCID: PMC8885157          DOI: 10.1055/s-0041-1742115

Source DB:  PubMed          Journal:  Clin Colon Rectal Surg        ISSN: 1530-9681


  42 in total

1.  Urethral Injury and Other Urologic Injuries During Transanal Total Mesorectal Excision: An International Collaborative Study.

Authors:  Patricia Sylla; Joep J Knol; Anthony P D'Andrea; Rodrigo O Perez; Sam B Atallah; Marta Penna; Roel Hompes; Albert Wolthuis; Philippe Rouanet; Abe Fingerhut
Journal:  Ann Surg       Date:  2021-08-01       Impact factor: 12.969

2.  Stereotactic navigation for TAMIS-TME.

Authors:  Sam Atallah; Sergio W Larach; John R T Monson
Journal:  Minim Invasive Ther Allied Technol       Date:  2016-06-27       Impact factor: 2.442

3.  Oncological safety of transanal total mesorectal excision (TaTME) for rectal cancer: mid-term results of a prospective multicentre study.

Authors:  Vicente Simo; Patricia Tejedor; Luis Miguel Jimenez; Cristina Hernan; Jaime Zorilla; Jorge Arrredondo; Fernando Lapuente; Carlos Pastor
Journal:  Surg Endosc       Date:  2020-04-24       Impact factor: 4.584

4.  NOTES transanal rectal cancer resection using transanal endoscopic microsurgery and laparoscopic assistance.

Authors:  Patricia Sylla; David W Rattner; Salvadora Delgado; Antonio M Lacy
Journal:  Surg Endosc       Date:  2010-02-26       Impact factor: 4.584

5.  Transanal total mesorectal excision for rectal cancer has been suspended in Norway.

Authors:  H H Wasmuth; A E Faerden; T Å Myklebust; F Pfeffer; S Norderval; R Riis; O C Olsen; J R Lambrecht; H Kørner; S G Larsen; H M Forsmo; O Baekkelund; S Lavik; J C Knapp; O Sjo; G Rashid
Journal:  Br J Surg       Date:  2019-12-05       Impact factor: 6.939

6.  Transanal Total Mesorectal Excision for Rectal Cancer: Outcomes after 140 Patients.

Authors:  Antonio M Lacy; Marta M Tasende; Salvadora Delgado; María Fernandez-Hevia; Marta Jimenez; Borja De Lacy; Antoni Castells; Raquel Bravo; Steven D Wexner; Richard J Heald
Journal:  J Am Coll Surg       Date:  2015-03-30       Impact factor: 6.113

7.  Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer: The ALaCaRT Randomized Clinical Trial.

Authors:  Andrew R L Stevenson; Michael J Solomon; John W Lumley; Peter Hewett; Andrew D Clouston; Val J Gebski; Lucy Davies; Kate Wilson; Wendy Hague; John Simes
Journal:  JAMA       Date:  2015-10-06       Impact factor: 56.272

8.  Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial.

Authors:  Seung-Yong Jeong; Ji Won Park; Byung Ho Nam; Sohee Kim; Sung-Bum Kang; Seok-Byung Lim; Hyo Seong Choi; Duck-Woo Kim; Hee Jin Chang; Dae Yong Kim; Kyung Hae Jung; Tae-You Kim; Gyeong Hoon Kang; Eui Kyu Chie; Sun Young Kim; Dae Kyung Sohn; Dae-Hyun Kim; Jae-Sung Kim; Hye Seung Lee; Jee Hyun Kim; Jae Hwan Oh
Journal:  Lancet Oncol       Date:  2014-05-15       Impact factor: 41.316

9.  Predictive Factors and Risk Model for Positive Circumferential Resection Margin Rate After Transanal Total Mesorectal Excision in 2653 Patients With Rectal Cancer.

Authors:  Sapho X Roodbeen; F B de Lacy; Susan van Dieren; Marta Penna; Frédéric Ris; Brendan Moran; Paris Tekkis; Willem A Bemelman; Roel Hompes
Journal:  Ann Surg       Date:  2019-11       Impact factor: 12.969

10.  COLOR III: a multicentre randomised clinical trial comparing transanal TME versus laparoscopic TME for mid and low rectal cancer.

Authors:  Charlotte L Deijen; Simone Velthuis; Alice Tsai; Stella Mavroveli; Elly S M de Lange-de Klerk; Colin Sietses; Jurriaan B Tuynman; Antonio M Lacy; George B Hanna; H Jaap Bonjer
Journal:  Surg Endosc       Date:  2015-11-04       Impact factor: 4.584

View more
  1 in total

1.  Importance of clinical research for the UK's 10-year cancer plan.

Authors:  Richard W Lee; Sarah Danson; Martin Elliot; Ed I Park; Thomas D Pinkney; Clare E Shaw; Dale Vimalachandran; Tim Maughan; Matt Seymour; Pippa Corrie; Jonathan Wadsley
Journal:  Lancet Oncol       Date:  2022-06-09       Impact factor: 54.433

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.